New combo therapy takes aim at Hard-to-Treat salivary gland cancer
NCT ID NCT07579598
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase II trial tests a combination of an antibody-drug conjugate (a targeted cancer drug) and stereotactic body radiotherapy (precise, high-dose radiation) in 40 people with recurrent or metastatic salivary gland cancer. Participants first receive the drug; if their disease stabilizes or shows limited progression, they also get radiation. The goal is to see if this approach shrinks tumors or controls the disease longer.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Becotatug Vedotin (antibody-drug conjugate) and stereotactic body radiotherapy
What this could lead to
If successful, this could offer a new treatment option for people with advanced salivary gland cancer that has spread or come back after standard therapy.
What could go wrong
This is a small, early-phase exploratory study with only 40 participants. It may not show enough benefit to move forward, and side effects from the drug or radiation could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.